Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mylan’s EpiPen Exclusivity Saved Again As Teva Reports CRL

This article was originally published in The Pink Sheet Daily

Executive Summary

Launching a competing epinephrine product has proved challenging, which is good news for Mylan. Teva disclosed the receipt of a complete response letter to its ANDA, just months after Sanofi voluntarily recalled Auvi-Q due to inaccurate dose delivery.


Related Content

Keeping Track: A Long-Awaited Approval For Generic EpiPen, Cancer Product Labels Expand And Constrict
Teva To Launch First Generic EpiPen In 'Coming Months'; FDA Heralds Approval Of Complex Product
Complex Generics May Be Part Of White House Drug Pricing Response
Generic Industry Wants More Guidance On Demonstrating Equivalence Of Drug-Device Combinations
Generic Combination Products May Be Permitted Delivery Device Variations
EpiPen Rival Heads Back To Market After kaléo Retools With ‘100% Automated’ Production
ANDAs For Drug/Device Combos Face High Bar At US FDA; Epipen, Advair May Benefit
EpiPen Generics: Woodcock Explains Injector Studies
EpiPen Familiarity May Prove Tough Hurdle For Generics
Mylan's EpiPen Nightmare Not Over Yet, But Will Congress Just Write?


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts